Kara S. Cox

Statistics

Publications

Citations

440

H-Index

Active since

2018

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

Kara S. Cox is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in immunology, infectious diseases, and molecular virology.

ORCID

Publications per year

2018–2022

Publications

A potent broadly neutralizing human RSV antibody targets conserved site IV of the fusion glycoprotein

Aimin Tang, Zhifeng Chen, Kara S. Cox et al. · Nature Communications · 2019 · 152 citations · Full text

Life Sciences, Immunology, Infectious Diseases +16

A phase 1, randomized, placebo-controlled study to evaluate the safety and immunogenicity of an mRNA-based RSV prefusion F protein vaccine in healthy younger and older adults

Antonios O. Aliprantis, Christine A. Shaw, Paul Griffin et al. · Human Vaccines & Immunotherapeutics · 2020 · 151 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +17

CD32 is expressed on cells with transcriptionally active HIV but does not enrich for HIV DNA in resting T cells

Mohamed Abdel‐Mohsen, Leticia Kuri-Cervantes, Judith Grau-Expósito et al. · Science Translational Medicine · 2018 · 102 citations · Full text

Life Sciences, Immunology, Infectious Diseases +17

A phase I randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, and immunogenicity of a live-attenuated quadrivalent dengue vaccine in flavivirus-naïve and flavivirus-experienced healthy adults

Kevin L. Russell, Richard Rupp, Javier O Morales-Ramirez et al. · Human Vaccines & Immunotherapeutics · 2022 · 35 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +17

1–4 of 4